Kava for Generalized Anxiety Disorder: A Review of Current Evidence
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Generalized anxiety disorder (GAD) is a chronic and debilitating condition characterized by persistent and overpowering anxiety. Treatment of GAD with antidepressants and benzodiazepines is only moderately effective and not free from side effects. Kava (Piper methysticum) has been explored as a potential phytotherapeutic option for GAD. OBJECTIVES: To perform a systematic review and meta-analysis of the available evidence on Kava as a treatment for GAD. METHODS: Systematic search of English-language publications from major databases for clinical trials reporting the effects of Kava for the treatment of GAD. RESULTS: Twelve articles were included in this review. Evidence supporting Kava as an effective treatment for GAD was found in two placebo-controlled trials and a reference-controlled trial. One negative trial demonstrated that Kava was not more effective than placebo. Meta-analyses of the results of three placebo-controlled trials (n = 130) favored Kava for GAD treatment with effect sizes between 0.59 and 0.99 (standard mean difference) without reaching statistical significance. Kava is an appealing treatment option to GAD patients who are more attune to natural remedies or lifestyle approaches to reduce stress. Positive patient experiences and improvement of vagal cardiac control due to Kava treatment were also reported in the literature. Kava is safe and well tolerated for short-term (4-8 weeks) therapeutic use at a dosage of 120-280 mg per day of Kavalactones, regardless of dosage schedule. CONCLUSIONS: Current evidence, although promising, is insufficient to confirm the effect of Kava for GAD treatment beyond placebo. New evidence is expected from a large, multisite ongoing trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zeng, X., Zhang, Y., Kwong, J. S. W., Zhang, C., Li, S., Sun, F., Niu, Y., & Du, L. (2015) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12141 · Cited by 2,082
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
Santarsieri, D., & Schwartz, T. (2015) · Drugs in Context · doi:10.7573/dic.212290 · Cited by 224
Chua, H. C., Christensen, E. T. H., Hoestgaard-Jensen, K., Hartiadi, L. Y., Ramzan, I., Jensen, A. A., Absalom, N. L., & Chebib, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157700 · Cited by 87
Kava in generalized anxiety disorder: three placebo-controlled trials
Connor, K. M., Payne, V., & Davidson, J. R. T. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00001 · Cited by 46 · cited 8×
“22 Hence, the placebo responsivity of GAD was a challenge in investigating this disorder, as noted by the authors.”
Influential
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“GABA-A receptor (244) None GAD (247) None”
BackgroundSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis
Zhang, W., Yan, Y., Wu, Y., Yang, H., Zhu, P., Yan, F., Zhao, R., Tian, P., Wang, T., Fan, Q., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106204 · Cited by 75
Trkulja, V., & Barić, H. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_22 · Cited by 28
Metadata
- Authors
- Ooi, S. L., Henderson, P., & Pak, S. C.
- Venue
- The Journal of Alternative and Complementary Medicine
- Publisher
- SAGE Publications
- Published
- 2018-08
- Volume
- 24
- Issue
- 8
- Pages
- 770-780
- ISSN
- 1075-5535 (ISSN-L)
- 1557-7708
- OpenAlex
- W2798144402
- Cited by
- 34
- References
- 4
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.